Blog Detail

Interesting New Research on Schizophrenia and Bipolar Disorder
46 Blogs

This week’s featured articles describe research in schizophrenia and bipolar disorder. They cover findings of both causation and treatment.

Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases.

Antti T, Heidi T, Mary C, David C, Jari T. Acta Psychiatr Scand. 2021 Mar 13. doi: 10.1111/acps.13295. Epub ahead of print. PMID: 33713343.

  • “We examined the incidence of schizophrenia and the catatonic subtype of schizophrenia over a 30-year period in Finland. We also investigated whether the incidence rate of the catatonic subtype of schizophrenia was linked to changes in exposure to viral infection (polio and measles) during the prenatal or infant period.”
  • “The results indicate that the incidence of schizophrenia in Finland has declined for individuals born between 1956 to 1989, and that the decline of catatonic schizophrenia may be partially attributable to eradication of polio.”

Brain structural alterations in pediatric bipolar disorder patients with and without psychotic symptoms.

Gao W, Cui D, Jiao Q, Su L, Yang R, Lu G. J Affect Disord. 2021 Mar 4;286:87–93. doi: 10.1016/j.jad.2021.02.077. Epub ahead of print. PMID: 33714175.

  • “Bipolar disorder (BD) with psychotic symptoms is a specific phenotype that presents greater risk of relapse and worse outcomes than nonpsychotic BD, however, the underlying mechanisms remain unknown and are less revealed in youth. Thus, the aims of the present study were to investigate brain structural alterations in pediatric bipolar disorder (PBD) patients with and without psychotic symptoms, and specifically to evaluate the impact of psychotic features on gray matter volume (GMV) in PBD patients.”
  • “The present findings suggested that psychotic features in PBD were associated with extensive brain structural lesions mainly located in the prefrontal-limbic-striatum circuit, which might represent the pathological basis of more sever symptoms in patients with psychotic PBD.”

Long-acting injectable antipsychotics: what, when, and how.

Citrome L. CNS Spectr. 2021 Mar 15:1–12. doi: 10.1017/S1092852921000249. Epub ahead of print. PMID: 33715640.

  • “Current guidelines for the treatment of patients with schizophrenia advocate that patients receive treatment with a long-acting injectable (LAI) antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence.”
  • “Additional approved indications in the United States for LAI antipsychotics include bipolar I disorder maintenance treatment for risperidone microspheres and aripiprazole monohydrate, and schizoaffective disorder for paliperidone palmitate once monthly.”

*** ***

The Treatment Scout website helps people find effective inpatient and residential care. It can also help you explore other intensive care options for mental health, addiction, etc. Find out more at http://www.treatmentscout.com/

Share on :